Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML

Stopped On 7/26/24 the Sponsor-Investigator was notified GlycoMimetics was terminating contracting for NCT05569512 following company restructuring. This notification came ahead of the study meeting criteria to progress from Phase 1 to Phase 2.

Conditions

• Acute Myeloid Leukemia
• Pediatric Cancer

Interventions

• DRUG: Uproleselan
• DRUG: Fludarabine
• DRUG: Clofarabine
• DRUG: Busulfan

Sponsor

Malika Kapadia

Collaborators

• [object Object]